Judy E. Garber, MD, MPH, of the Dana-Farber Cancer Institute, gives her expert perspective on this vital and timely topic.
Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer (Abstract S5-04).
Mitchell Dowsett, PhD, of the Royal Marsden Hospital discusses the EndoPredict test, which has improved performance compared with the widely used Oncotype Dx test (Abstract S3-01).
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Carlos L. Arteaga, MD, of Vanderbilt University, discuss the roles of IGF/insulin signaling, adipokines and inflammation, and metformin and lifestyle change in breast cancer and risk for the disease.
Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' plenary lecture.
Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Abstract S2-05).
